Skip to main content
NIH funding notice RFA-DA-19-022

Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional)

Closed on March 19, 2019.

Posted
January 9, 2019
Close date
March 19, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $209,892 in first-year total cost, median $209,892.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 IXR-Q (11)]1

Most frequent institutions

  1. RISSANA, LLC1
Competing awards under RFA-DA-19-022 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019A mobile technology to extend the reach of primary care for opioid misuse1R41DA050232-01CAVAZOS-REHG, PATRICIA AGOODMAN, MICAHRISSANA, LLC, MO$209,892ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.